Search research articles
Contact Us
Filters
Showing results (461-470 of 1,211) with videos related to
Page
of 122
Sort By:
Journal of Cardiac Failure
|
April 9, 2023
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial)
Tor Biering-Sørensen, Mats C Højbjerg Lassen, Amil Shah, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
August 9, 2011
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD
Akshay S Desai, Robert Toto, Petr Jarolim, et al.
Journal of the American College of Cardiology
|
June 11, 2025
Re-Evaluating Recurrent Events in Heart Failure Trials: Patterns, Prognostic Implications, and Analytical Improvements
Audinga-Dea Hazewinkel, John Gregson, Stuart J Pocock, et al.
European Journal of Heart Failure
|
July 7, 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Stuart J Pocock, João Pedro Ferreira, Milton Packer, et al.
Circulation
|
May 5, 2016
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
Naoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
Journal of Cardiac Failure
|
February 16, 2023
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event
Robert J Mentz, Jonathan H Ward, Adrian F Hernandez, et al.
European Journal of Heart Failure
|
September 1, 2024
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial
Henri Lu, Brian L Claggett, Milton Packer, et al.
Nature Medicine
|
May 10, 2026
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Johann Bauersachs, Scott D Solomon, Stefan D Anker, et al.
European Journal of Heart Failure
|
March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Annals of Internal Medicine
|
December 19, 2022
Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study
Ankit Maheshwari, Faye L Norby, Riccardo M Inciardi, et al.
Page
of 122
Search research articles
Search
Showing results (461-470 of 1,211) with videos related to
Sort By:
Page
of 122
Journal of Cardiac Failure
|
April 9, 2023
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial)
Tor Biering-Sørensen, Mats C Højbjerg Lassen, Amil Shah, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
August 9, 2011
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD
Akshay S Desai, Robert Toto, Petr Jarolim, et al.
Journal of the American College of Cardiology
|
June 11, 2025
Re-Evaluating Recurrent Events in Heart Failure Trials: Patterns, Prognostic Implications, and Analytical Improvements
Audinga-Dea Hazewinkel, John Gregson, Stuart J Pocock, et al.
European Journal of Heart Failure
|
July 7, 2022
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Stuart J Pocock, João Pedro Ferreira, Milton Packer, et al.
Circulation
|
May 5, 2016
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
Naoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
Journal of Cardiac Failure
|
February 16, 2023
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event
Robert J Mentz, Jonathan H Ward, Adrian F Hernandez, et al.
European Journal of Heart Failure
|
September 1, 2024
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trial
Henri Lu, Brian L Claggett, Milton Packer, et al.
Nature Medicine
|
May 10, 2026
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Johann Bauersachs, Scott D Solomon, Stefan D Anker, et al.
European Journal of Heart Failure
|
March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Annals of Internal Medicine
|
December 19, 2022
Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study
Ankit Maheshwari, Faye L Norby, Riccardo M Inciardi, et al.
Page
of 122